Literature DB >> 11004688

Malignant hypertension - the role of the paracrine renin-angiotensin system.

S Fleming1.   

Abstract

Malignant hypertension remains one of the life-threatening complications of blood pressure elevation. It is a clinico-pathological syndrome of severe blood pressure elevation combined with malignant vascular injury. This is a characteristic form of vascular damage, with two elements: fibrinoid necrosis and endarteritis proliferans. Although the morphology of these has been well described, the molecular events are not fully understood. This review summarizes the evidence from transgenic animals for a role for the activation of a local paracrine renin-angiotensin system in the pathogenesis of malignant vascular injury. These animal models provide pathological, pharmacological, and genetic evidence supporting the hypothesis that intra-renal generation of angiotensin 2 and exposure of the microcirculation to elevated blood pressure co-operate in causing tissue damage in malignant hypertension. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004688     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH674>3.0.CO;2-Q

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.

Authors:  Karen A Griffin; Aaron Polichnowski; Natalia Litbarg; Maria Picken; Manjeri A Venkatachalam; Anil K Bidani
Journal:  Hypertension       Date:  2014-06-23       Impact factor: 10.190

2.  Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats.

Authors:  Su-li Zhang; Yun-hui Du; Jin Wang; Li-hong Yang; Xiao-li Yang; Rong-hua Zheng; Ye Wu; Ke Wang; Ming-sheng Zhang; Hui-rong Liu
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

Review 3.  Hypertensive crisis in children.

Authors:  Jayanthi Chandar; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2011-07-20       Impact factor: 3.714

4.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

5.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

6.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

7.  CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury.

Authors:  Hongdong Huang; Yang Luo; Yumei Liang; Xidai Long; Youming Peng; Zhihua Liu; Xiaojun Wen; Meng Jia; Ru Tian; Chengli Bai; Cui Li; Fuliang He; Qiushi Lin; Xueyan Wang; Xiaoqun Dong
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

8.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

9.  Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.

Authors:  Andrew Advani; Darren J Kelly; Suzanne L Advani; Alison J Cox; Kerri Thai; Yuan Zhang; Kathryn E White; Renae M Gow; Sally M Marshall; Brent M Steer; Philip A Marsden; P Elizabeth Rakoczy; Richard E Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 10.  Clinical review: the management of hypertensive crises.

Authors:  Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2003-07-16       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.